HOME >> MEDICINE >> NEWS
Experimental therapies and vaccines for Ebola and Marburg viruses focus of Academy meeting

Recent outbreaks of Ebola and Marburg virus infections in Africa have been characterized by two remarkable features they have been unusually sustained and have maintained extremely high fatality rates. These two features have underscored the need to expand our current understanding of these fatal hemorrhagic diseases and to accelerate progress towards protective vaccines and novel therapeutic strategies.

To present news on the latest developments in our understanding of the molecular biology, epidemiology and approaches to vaccine development for these acute hemorrhagic viruses, the New York Academy of Sciences' Emerging Infectious Diseases Discussion Group is sponsor ing a meeting, Ebola and Marburg Viruses--Perspective 2005 on Thursday, June 2 at 5 p.m. The event will take place at the New York Academy of Sciences headquarters at 2 East 63rd Street, New York.

Speakers and topics will include:

Christopher Basler, Mount Sinai School of Medicine
"Antagonism of the Host Interferon Response by Ebola Viruses."

Daniel Bausch, Tulane University School of Medicine
"Controlling Marburg and Ebola Hemorrhagic Fevers: Where We've Been and Where We Need to Go."

Thomas Geisbert, United States Army Medical Research Institute of Infectious Diseases
"Countermeasures Against Ebola Virus and Marburg Virus: Advances and Challenges."

For more information, please visit the meetings/conferences section of the nyas.org web site


'"/>

Contact: Jennifer Tang
jtang@nyas.org
212-838-0230 x257
New York Academy of Sciences
24-May-2005


Page: 1

Related medicine news :

1. Experimental gene therapy abolishes arthritis pain and lessens joint damage
2. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
3. Experimental flu vaccine appears promising in early tests
4. Experimental ragweed therapy offers allergy sufferers longer relief with fewer shots
5. Experimental medication kicks depression in hours instead of weeks
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental shingles vaccine proves effective in nationwide study
8. Future therapies for stroke may block cell death
9. Antifolate therapies found effective against certain type of malaria
10. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
11. A sweet step toward new cancer therapies

Post Your Comments:
(Date:6/19/2013)... 2013 Weight gain and obesity have ... concerns including heart disease, kidney failure and high blood ... excess and unnecessary fat, have many people searching for ... hCG diets to not only allow patients to ... also aim to reduce the risk for many weight-related ...
(Date:6/19/2013)... To survive when your plane goes down on a combat mission, ... the most important item in a survival kit is not a ... Kleyne Hour Power of Water radio show, Orr stated that in ... ahead of guns or even food. , According to Orr, the ... carry on planes in Vietnam. He was the only Navy pilot ...
(Date:6/19/2013)... New York,NY (PRWEB) June 19, 2013 ... company officials at SizeItUp formally announced the ... This smartly renovated van is the latest entry in ... for the year 2013. The completely redesigned 2012 Nissan ... the automobile lovers and critics alike. , Provided with ...
(Date:6/19/2013)... McGuff Pharmaceuticals, Inc. continues to ... (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple ... fomerly known as Delalutin™. We are providing this ... approval and market introduction dates for McGuff’s Hydroxyprogesterone Caproate ... our pending ANDA, to date, McGuff has responded to ...
(Date:6/19/2013)... 2013 Audibel Hearing Center is ... tinnitus patients, the A2 with Multiflex Tinnitus Technology. ... ringing in the ears. Although bothersome, tinnitus usually ... body. , Using their patent-pending Multiflex Tinnitus Technology, ... comforting sound stimulus that resonates through the patient’s ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Vietnam Navy Pilot Reveals to Radio Host Sharon Kleyne That He Carried Extra Water Not a Gun in Survival Kit 2Health News:Rim Fitments Expert, SizeItUp Comes Up With Database Integrations For The 2012 Nissan NV 2Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2
(Date:6/19/2013)... 19, 2013 Pharma IQ is pleased ... summary of the results from an industry survey conducted ... respondents stated that CROs would be an area of active ... be running 6 or more clinical trials in the BRIC ... Supply USA Summit explores the latest ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... 2013  Actavis, Inc. (NYSE: ACT ) today ... U.S. Securities and Exchange Commission (SEC) a registration statement on ... Warner Chilcott plc (NASDAQ: WCRX ), which ... Chilcott (the "Form S-4"). As previously announced ... have entered into a definitive agreement pursuant to which Actavis ...
Breaking Medicine Technology:Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
Cached News: